Category Archives: Testosterone Replacement Therapy

A Long Island man is facing a host of charges for allegedly posing as a medical professional and running an illegal health clinic, where he treated patients.

Brian Michael Kaufman, 45, of Smithtown, allegedly ran Mens Health Solution of Smithtown on Middle Country Road, despite not having a medical license, Suffolk County DA Tim Sini announced.

He allegedly treated patients, including testosterone and steroid injections.

The investigation into Kaufmans practice determined that he allegedly has been operating the medical practice since at least August last year.

When he was arrested, Kaufman admitted to investigators that he was not licensed to practice any medical profession and had no training to provide medical services or provide testosterone replacement therapy, the DA said.

Mens Health Solution of Smithtown has since shuttered its doors.

"This individual put lives in danger and posed a clear threat to public health by masquerading as a medical practitioner," Sini said in a statement. "He did not have patients; he had victims. We are asking those victims to please contact the District Attorney's Office with any information they may have about Kaufman's alleged scam."

Kaufman has been charged with:

"This case is significant because it unearthed a convicted felon playing doctor who jeopardized his 'patients' lives," DEA agent Ray Donovan said. "In order to safeguard our communities, law enforcement has to act fast when they see someone threatening public health and safety.

"In this case, Brian Kaufman's alleged testosterone trafficking ring put people in harm's way while committing several crimes."

If convicted, Kaufman faces up to seven years in prison on the top count. He was arraigned this week and released with a GPS monitoring device. He will also be subjected to drug testing and is under travel restrictions.

Anyone who has received medical services from Kaufman or at Mens Health of Smithtown has been asked to contact the Suffolk County District Attorneys Office by calling (631) 853-8087.

Click here to sign up for Daily Voice's free daily emails and news alerts.

Read more:
Man Accused Of Running Illegal Long Island Health Clinic - Daily Voice

What do parents do when they learn their daughter suddenly wants to be a boy? When Rene entered puberty, she began to change, her hair becoming shorter and shorter, her dress more androgynous. Parents Birgid and Michael initially thought she was just trying things out, until one day Rene outed herself as transgender during a family walk. Her parents were relieved, but also very worried about what it could mean for the future. They found an experienced youth psychotherapist to accompany Rene closely for the next few years as she became Ren. After a year of psychotherapy, the therapist recommended hormone replacement therapy. The testosterone quickly changed Rens body: his voice broke, his hair became thicker and his whole posture more male. For him it was a liberation, but Birgid has to struggle with the loss of a daughter for good. How will Ren develop now? What other changes will hormone therapy bring, and what will it do to him? Its the start of a long journey for Ren and his parents.

Go here to see the original:
In the Wrong Body - Teen Girl to Teen Boy - Deutsche Welle

Jatenzo (testosterone undecanoate; Clarus Therapeutics), an oral testosterone replacement therapy, is now available for the treatment of hypogonadism.

Specifically, Jatenzo is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:

Jatenzo is not intended for use in males with age-related hypogonadism and its safety and efficacy have not been established in males <18 years old.

The treatment carries a Boxed Warning related to blood pressure (BP) increases that could potentially increase the risk of major adverse cardiovascular events. In a clinical trial, Jatenzo increased systolic BP during 4 months of treatment by an average of 4.9 mmHg based on ambulatory BP monitoring and by an average of 2.8 mmHg from baseline based on BP cuff measurements. For this reason, baseline cardiovascular risk should be considered before initiating therapy and BP should be adequately controlled. Among study patients treated with Jatenzo, 7% were started on antihypertensive medications or required intensification of their antihypertensive medication regimen during the 4-month trial.

Jatenzo, a Schedule III controlled substance, is available in 158mg, 198mg, and 237mg softgels. Dosage should be individualized based on serum testosterone concentrations.

Jatenzo offers patients a convenient softgel formulation, and eliminates the worry of gel transference, skin irritation from patches, or pain from injections that other testosterone treatments carry, said Dr Ronald S. Swerdloff, lead investigator of the inTUne trial, the pivotal study that established the safety and efficacy of the treatment.

For more information visit jatenzo.com.

This article originally appeared on MPR

Read this article:
Jatenzo, an Oral Testosterone Replacement Therapy, Now Available - Renal and Urology News

MedicalResearch.com Interview with:

Robert E. Dudley, Ph.D.Chairman, Chief Executive Officer and PresidentClarus Therapeutics

Dr. Dudley discusses the recent announcement that Clarus Therapeutics, Inc. has launched JATENZO (testosterone undecanoate) capsules for the treatment of appropriate men with testosterone deficiency (hypogonadism):

MedicalResearch.com: What is the background for this announcement?

Response: JATENZOis the first and only oral softgel testosterone undecanoate and the first oral testosterone product approved by the U.S. FDA in more than 60 years.JATENZO is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

The launch of JATENZO means that physicians and men living with testosterone deficiency due to genetic or structural abnormalities finally have a safe and effective oral testosterone replacement therapy. We are proud to commercially launch this unique oral formulation to healthcare providers and the appropriate patients who they treat. JATENZO is now available at pharmacies across the country.

MedicalResearch.com: What are the main findings of the underlying studies?

Response: JATENZO was evaluated in a Phase 3 pivotal trial among 166 adult, hypogonadal men in a 4-month, open-label study with a topical testosterone comparator arm. The starting dose was 237 mg twice daily (BID) with meals. Dose adjustments (minimum 158 mg BID; maximum 396 mg BID) were made roughly 3 and 7 weeks after initiation of JATENZO based on average circulating testosterone concentration levels. 87% of JATENZO patients reached testosterone levels within the normal eugonadal range at the end of the study; peak testosterone levels were in close alignment with FDA targets.

Across all Phase 2 and Phase 3 trials combined, the safety of JATENZO has been evaluated in 569 patients who were treated with JATENZO for up to two (2) years. Liver toxicity was not observed with JATENZO in clinical trials.

Mild gastrointestinal adverse events observed with JATENZO were transient, manageable and did not lead to discontinuation.Decreased HDL cholesterol and increased hematocrit were associated with JATENZO use but did not lead to discontinuation of JATENZO. Only three of the 166 patients (1.8%) in the 4-month study experienced adverse reactions that led to premature discontinuation from the study, including rash (n=1) and headache (n=2). JATENZO was associated with an increase in systolic blood pressure. A boxed warning about the potential risks associated with elevated blood pressure appears on JATENZO labeling. Patients on JATENZO should have their blood pressure monitored.

Among the 569 patients who received JATENZO in all Phase 2 and 3 trials combined, the following adverse reactions were reported in >2% of patients: polycythemia, diarrhea, dyspepsia, eructation (i.e., burping), peripheral edema, nausea, increased hematocrit, headache, prostatomegaly (i.e., enlarged prostate), and hypertension.

MedicalResearch.com: How doesJATENZO differ from other treatments for testosterone deficiency?

Response: The launch of JATENZO is an important step forward in testosterone replacement therapy. The only other oral testosterone replacement therapy product ever approved by the FDA is methyltestosterone (an alkylated androgen) that has been associated with serious liver toxicity and is rarely, if ever, used today. Because JATENZO is formulated as a lipophilic prodrug, it bypasses the first-pass hepatic metabolism. No liver toxicity-related events were observed in clinical studies of JATENZO including in patients who took JATENZO at higher doses than recommended in current product labeling for two (2) years.

We believe JATENZO addresses a long-standing need for a safe and effective oral testosterone replacement product that meets current day FDA safety and efficacy standards. JATENZO enters a market where the vast majority of hypogonadal men are treated with injectable or topical testosterone products. JATENZO avoids administration challenges seen with these non-oral treatments it presents no injection site pain, no transfer risk, no mess, no skin irritation and no surgical procedure. Therefore, we believe a significant number of hypogonadal men will prefer JATENZO as an alternative to other forms of testosterone therapy.

MedicalResearch.com: How are men tested to determine ifJATENZO therapy is appropriate for them?

Response: According to the American Urological Association and Endocrine Society clinical guidelines, diagnosis of hypogonadism is determined by both the identification of symptoms and/or signs consistent with hypogonadism and blood test measurement of low morning total serum testosterone concentration (defined as <300 ng/dL, on two separate days). Healthcare providers should assess each patient individually for the appropriateness of JATENZO to treat their clinical hypogonadism.

MedicalResearch.com: What else should readers take away from your report?

Response: Clinical hypogonadism can be more complex than most people realize and left untreated, can have a profound negative impact for the individual. Men with the symptoms of hypogonadism have a real medical need that deserves appropriate diagnosis and treatment.

Any disclosures?

Pleaseclick herefor full Prescribing Information, including BOXED WARNING on increases in blood pressure.

Citation:

CLARUS THERAPEUTICS ANNOUNCES COMMERCIAL LAUNCH AND AVAILABILITY OF JATENZO (TESTOSTERONE UNDECANOATE) CAPSULES, CIII FOR THE TREATMENT OF HYPOGONADISM

We respect your privacy and will never share your details.

Feb 19, 2020 @ 12:05 pm

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Read more from the original source:
Clarus Therapeutics Lauches JATENZO - Oral Testosterone Replacement Therapy - MedicalResearch.com

This intelligence report provides a comprehensive analysis of the Testosterone Replacement Therapy Market. This includes Investigation of past progress, ongoing market scenarios, and future prospects. Data True to market on the products, strategies and market share of leading companies of this particular market are mentioned. Its a 360-degree overview of the global markets competitive landscape. The report further predicts the size and valuation of the global market during the forecast period.

Testosterone is responsible for the development of male sexual characteristics and this hormone formed by the testicles. Insufficient production of testosterone causes erectile dysfunction. Testosterone Replacement Therapy (TRT) is generally termed as hormone therapy for men, designed to counteract the effects of reduced activity in the gonads or hypogonadism. Hypogonadism in men is clinical syndrome, which results in the failure of the testes to produce physiological levels of testosterone. Erectile dysfunction arises due to reduce testosterone production to overcome this testosterone replacement therapy is used to improve the problem.

Major Players in this Report Include,

AbbVie Inc. (United States), Endo International (Ireland), Eli Lilly and Company (United States), Pfizer (United States), Bayer (Germany), Actavis (Allergan) (United States), Novartis (Switzerland), Teva (Israel), Ferring Pharmaceuticals (Switzerland), Kyowa Kirin (Japan) and Mylan (United States).

Free Sample Report + All Related Graphs & Charts: https://www.advancemarketanalytics.com/sample-report/46424-global-testosterone-replacement-therapy-market

Each segment and sub-segment is analyzed in the research report. The competitive landscape of the market has been elaborated by studying a number of factors such as the best manufacturers, prices and revenues. Global Testosterone Replacement Therapy Market is accessible to readers in a logical, wise format. Driving and restraining factors are listed in this study report to help you understand the positive and negative aspects in front of your business.

This study mainly helps understand which market segments or Region or Country they should focus in coming years to channelize their efforts and investments to maximize growth and profitability. The report presents the market competitive landscape and a consistent in depth analysis of the major vendor/key players in the market.

Market Drivers

Market Trend

Restraints

Opportunities

Challenges

Furthermore, the years considered for the study are as follows:

Historical year 2013-2017

Base year 2018

Forecast period** 2019 to 2025 [** unless otherwise stated]

**Moreover, it will also include the opportunities available in micro markets for stakeholders to invest, detailed analysis of competitive landscape and product services of key players.

The titled segments and Market Data Breakdown are illuminated below:

By Type: Creams or Gels, Patches, Injections, Buccal Adhesives, Implants, Oral

Application: Hospitals, Clinics

For Early Buyers | Get Up to 20% Discount on This Premium Report: https://www.advancemarketanalytics.com/request-discount/46424-global-testosterone-replacement-therapy-market

Region Included are: North America, Europe, Asia Pacific, Oceania, South America, Middle East & Africa

Country Level Break-Up: United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.

Strategic Points Covered in Table of Content of Testosterone Replacement Therapy Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Testosterone Replacement Therapy Market.

Chapter 2: Exclusive Summary the basic information of the Testosterone Replacement Therapy Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the Testosterone Replacement Therapy

Chapter 4: Presenting the Testosterone Replacement Therapy Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying the by Type, End User and Region 2013-2018

Chapter 6: Evaluating the leading manufacturers of the Testosterone Replacement Therapy market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Finally, Testosterone Replacement Therapy Market is a valuable source of guidance for individuals and companies.

For More Information and Customization: https://www.advancemarketanalytics.com/enquiry-before-buy/46424-global-testosterone-replacement-therapy-market

Key questions answered

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:

Advance Market Analytics is Global leaders of Market Research Industry provides the quantified B2B research to Fortune 500 companies on high growth emerging opportunities which will impact more than 80% of worldwide companies revenues.

Our Analyst is tracking high growth study with detailed statistical and in-depth analysis of market trends & dynamics that provide a complete overview of the industry. We follow an extensive research methodology coupled with critical insights related industry factors and market forces to generate the best value for our clients. We Provides reliable primary and secondary data sources, our analysts and consultants derive informative and usable data suited for our clients business needs. The research study enable clients to meet varied market objectives a from global footprint expansion to supply chain optimization and from competitor profiling to M&As.

Contact Us:

Craig Francis (PR & Marketing Manager)

AMA Research & Media LLP

Unit No. 429, Parsonage Road Edison, NJ

New Jersey USA 08837

Phone: +1 (206) 317 1218

[emailprotected]

Tags: Global Testosterone Replacement Therapy MarketTestosterone Replacement Therapy MarketTestosterone Replacement Therapy Market GrowthTestosterone Replacement Therapy Market ShareTestosterone Replacement Therapy Market SizeTestosterone Replacement Therapy Market Trends

Go here to see the original:
Testosterone Replacement Therapy analysis by stage of development - TechNews.mobi

In a multinational randomized phase 3 trial, once-weekly somapacitan demonstrated superiority over placebo for treatment of patients with adult growth hormone (GH) deficiency, according to study results published in The Journal of Clinical Endocrinology & Metabolism.

Hormone replacement is a common component of care for patients with hypopituitarism, but its daily subcutaneous injections can be burdensome for some patients. This burden may result in reduced compliance or adherence or in an unwillingness on the part of physicians to add to their patients treatment burden. Long-acting alternatives to daily injections could reduce the burden of treatment and thus lower the barrier to therapy.

Somapacitan is a novel once-weekly reversible albumin-binding GH derivative, with a similar long-lasting mechanism as insulin detemir. Studies have shown once-weekly somapacitan to be well tolerated in healthy adults, but none have examined its efficacy in adult GH deficiency treatment.

To evaluate this, researchers randomly assigned 301 patients with adult GH deficiency at 92 sites in 17 countries in a 2:1:2 ratio to receive once-weekly somapacitan, once-weekly placebo, or daily GH for 34 weeks. Patients 23 to 79 years of age with a diagnosis of adult- (69.7%) or childhood-onset (30.3%) adult GH deficiency who were naive to GH treatment or had no exposure to GH therapy for 180 days prior to treatment assignment were included. This main period of 34 weeks was followed by an extension period to examine longer-term use.

The main period was double blinded for the somapacitan and placebo cohorts but open label for daily GH use. Investigators and trial sites remained blinded throughout the entire trial. Dose titration occurred during the first 8 weeks of the main trial until a steady state insulinlike growth factor-1 (IGF-1) standard deviation score (SDS) of -0.5 to +1.75 was achieved. The remaining 26 weeks consisted of fixed-dose treatment.

The 52-week open-label extension period allowed for evaluation of efficacy and safety of somapacitan for up to 86 weeks of treatment. Patients who had been receiving somapacitan continued to do so (somapacitan/somapacitan group), those receiving placebo were switched to somapacitan (placebo/somapacitan group), and those receiving daily GH were randomly assigned 1:1 to continue with daily GH (daily GH/daily GH group) or to switch to somapacitan (daily GH/somapacitan group).

At week 34, somapacitan reduced truncal fat percentage from baseline by 1.06% compared with a 0.47% increase for placebo (estimated treatment difference, -1.53%; 95% CI, -2.68 to -0.38; P =.009), demonstrating superiority over placebo. Compared with placebo, the somapacitan group also had decreased visceral fat and increased lean body mass and appendicular skeletal muscle mass at week 34.

Similar changes in visceral fat, total lean body mass, and appendicular skeletal muscle mass were observed in the somapacitan and daily GH groups at week 34. A less pronounced reduction in truncal fat percentage was observed with somapacitan treatment compared with daily GH treatment at week 34. No significant difference in body weight from baseline to week 34 was observed for the somapacitan (+1.40 kg) or placebo (+0.39 kg) groups, but was observed between somapacitan and daily GH (+0.27 kg; estimated treatment difference, 1.13 kg; 95% CI, 0.13-2.12) groups.

At week 86, there were no notable differences between the somapacitan and daily GH groups for percentage change in visceral fat, lean body mass, or appendicular skeletal muscle mass, and improvements in visceral fat and lean body mass were maintained. However, treatment effects on other body composition measures were less pronounced with somapacitan treatment vs daily GH therapy. For patients who switched from placebo to somapacitan in the extension period, improvements were observed in all body composition measures to a similar degree as with long-term daily GH treatment.

No significant differences in mean levels of corrected total bone mineral content or density from baseline to week 86 in the somapacitan and daily GH groups were observed, nor was there a significant difference in these levels between these 2 groups.

Two individuals had severe adverse events that were possibly related to trial products during the study period. One was a patient in the daily GH/no treatment group, who was also receiving testosterone and suffered a life-threatening hemoconcentration, but recovered with treatment. The other patient was in the daily GH/somapacitan group and was diagnosed with bladder transitional cell carcinoma in week 80, but went on to complete the trial.

One of the concerns about continuous exposure to GH is that it may result in negative effects on insulin sensitivity and glucose metabolism. In this trial, fasting plasma glucose and hemoglobin A1c values did not increase over 86 weeks, and there were no new cases of diabetes in patients treated with somapacitan. The limited negative effects paired with somapacitans potentially superior effects on visceral fat reduction vs placebo by week 34 of treatment suggest that somapacitan may provide an effective alternative to daily GH in adults with GH deficiency.

Some limitations of this study included the reliance on patient reporting for adherence to treatment as well as the open-label nature of the daily GH treatment group. In addition, some patients in the active drug groups had IGF-1 SDS values below -2 at the end of the titration period and so may not have received the full benefit of GH replacement. Finally, the less pronounced effect of somapacitan on truncal fat and body weight when compared with daily GH over the long term cannot be explained by a different response in IGF-1 SDS, as mean levels and distributions were similar.

Disclosure: This study was funded by Novo Nordisk, the manufacturer of somapacitan. All but one author on the study has received either employment, contract work, or funding from Novo Nordisk.

Follow @EndoAdvisor

Reference

Johannsson G, Gordon MB, Rasmussen MH, et al. Once-weekly somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial [published online February 5, 2020]. J Clin Endocrinol Metab. doi:10.1210/clinem/dgaa049

See the article here:
Once-Weekly Treatment for Adult GH Deficiency Effective in Phase 3 Trial - Endocrinology Advisor

The ' Fire Damper market' research report now available with Market Study Report, LLC, is a compilation of pivotal insights pertaining to market size, competitive spectrum, geographical outlook, contender share, and consumption trends of this industry. The report also highlights the key drivers and challenges influencing the revenue graph of this vertical along with strategies adopted by distinguished players to enhance their footprints in the Fire Damper market.

The recent study of the Fire Damper market is an exhaustive examination of this industry, and contains insights pertaining to important parameters of this business space. The research report provides details about the prevailing market share, industry trends, market size, renumeration estimates, periodic deliverables, and price projections over the analysis period.

Request a sample Report of Fire Damper Market at:https://www.marketstudyreport.com/request-a-sample/2498823?utm_source=itresearchbrief.com&utm_medium=Abhijeet

The document gives credible data regarding the key investment pockets of the Fire Damper market, alongside the growth pattern followed by the industry over the forecast period. Having said that the report focuses on the challenges present in the industry and growth projections which are anticipated to dictate this industry in the coming years.

Key highlights of the Fire Damper market report:

Exploring the geographical hierarchy of the Fire Damper market:

Fire Damper Market segmentation:

Key takeaways of regional assessment presented in Fire Damper market study:

Product type and application scope of Fire Damper market:

Product scope:

Product types:

Top pointers listed in the report:

Application scope:

Application partition:

Insights entailed in the report:

Ask for Discount on Fire Damper Market Report at:https://www.marketstudyreport.com/check-for-discount/2498823?utm_source=itresearchbrief.com&utm_medium=Abhijeet

Analyzing the competitive backdrop of Fire Damper market:

Industry majors:

Key parameters included in the report which define the competitive spectrum:

Other takeaways from the Fire Damper market report:

For More Details On this Report:https://www.marketstudyreport.com/reports/global-fire-damper-market-growth-2020-2025

Some of the Major Highlights of TOC covers:

Executive Summary

Manufacturing Cost Structure Analysis

Development and Manufacturing Plants Analysis of Fire Damper

Key Figures of Major Manufacturers

Related Reports:

2. Global Air Separation Plant Market Growth 2020-2025Air Separation Plant Market report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Air Separation Plant by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.Read More: https://www.marketstudyreport.com/reports/global-air-separation-plant-market-growth-2020-2025

Read More Reports On: https://www.marketwatch.com/press-release/Testosterone-Replacement-Therapy-Market-Size-Revenue-to-Reach-USD-14602-million-By-2025-2020-02-18

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Read more:
Latest Study explores the Fire Damper Market Witness Highest Growth in near futu - ITResearchBrief.com

Carol Vorderman is one happy lady!

The 58-year-old telly star has taken to Twitter to share that's she's happier than ever, and could "burst" in a rather cryptic post.

Sharing the update with her 424k loyal followers, the former Countdown star asked:

"Ever been so happy you could actually burst?"

Carol then went on to gush about the fact she's feeling over the moon all the time, and hasn't had a down day for as long as she can remember.

She continued: "I'm feeling like that 7 days a week now....every little pleasure makes me grin... Always been a very happy soul, but it's like it's become ephemeral".

Fans speculated her message might have something to so with her love life, but Carol has since tweeted back to insist that's not true.

She wrote: "It was about being happy, and nothing to do with sex. Life's never dull eh?"

One told told the TV star: "You shouldn't hide your happiness just because social media is such a negative space."

While another quipped: "You deserve this happiness and even more. Don't shy away from sharing your joy with the world!".

It comes after Carol, who is usually notoriously secret about her love life, dropped some huge hints in a newspaper interview last year.

Carol, who is believed to be single, admitted she enjoys a very active sex life in an interview with the Daily Mail.

She said: "I get up to a lot of mischief. I have a number of special friends - but Im not doing anything wrong.

"Everyones single. And yes, apart from one, theyre all younger than me."

The mum to two grown children said that she will never reveal the names of who she is dating.

Carol also said she feels she deserves more "me time" after years of caring for others, including her beloved mum who passed away two years ago.

The former Countdown star also opened up about the benefits of her menopause medication - supplemented with testosterone and oestregen gels - which she claims has enhanced her bum and bust.

Carol said she takes the hormone replacement therapy alongside plant-derived natural bio-identical hormones.

She told reporters that this was the reason behind her gravity-defying figure and her increased libido.

Originally posted here:
Carol Vorderman says she could 'burst with happiness' as 'every little pleasure' makes her 'grin' - Mirror Online

Q: A recent news release suggested that men with low testosterone levels may have improvement in sexual function and quality of life. How can I determine whether I can benefit and what questions should I ask my doctor?

A: Before we get into the details of the newly reported benefits of testosterone therapy including the scope of those benefits and the men most likely to see them lets talk about what, exactly, testosterone is, what it does, and what constitutes low levels (also sometimes referred to as low T, andropause, or even male menopause).

To start with, testosterone is the most important male hormone (although women have measurable levels as well). In a nutshell, its what makes men men at least physically. Its manufactured in the testicles and plays a significant role in puberty (including penis and testicle growth and voice deepening), muscle and bone growth and development, strength, sex drive, and fertility.

Testosterone levels are usually measured with a blood test and are reported in terms of nanograms per deciliter (abbreviated as ng/dL). The normal range for men 20-70 is 300-1000 ng/dL. However, starting at about age 30, mens levels gradually decrease by an average of 1-2% per year. According to the journal Annals of Internal Medicine, the symptoms of low testosterone include little or no interest in sex, erectile dysfunction, less energy/feeling weak, mood changes and feeling depressed, loss of bone mineral density, and loss of body and facial hair. However, there is significant debate as to whether these symptoms are truly associated with low testosterone or if they are a result of other factors, such as chronic illness or certain medications.

Studies have found that 20%-40% of males ages 30-70 have low testosterone levels (although its important to note that not all of them will have any negative symptoms).

Okay, now lets talk about the news stories you may have heard about. The study in question evaluated 38 other high-quality studies and focused on men with age-related low testosterone and the effects of testosterone replacement therapy (TRT). The findings were fairly limited: Overall, men who received TRT experienced small improvements in sexual function and quality of life. The researchers did not find that TRT offered any benefits for other age-related issues, such as lack of energy, mood, strength, memory, or cognitive ability. And they were unable to shed any new light on any of the previously reported links between testosterone replacement therapy and heart health, prostate cancer, or mortality.

So, what should you do if you think you might have age-related low testosterone? The Washington DC-based non-profit, Mens Health Network (menshealthnetwork.org), recommends that you discuss your symptoms with your doctor and ask for a blood test. If your levels come back low, you should ask your doctor the following questions recommended by the American College of Physicians (ACP): Will taking TRT help with the symptoms that I came to discuss with you? What method of TRT is best for me? What are the risks and side effects of treatment? And How long will it take for TRT to work, and what if it does not work?

Mens Health Network supports the ACPs guidelines, which recommend that doctors consider offering TRT via intramuscular injection rather than a patch, gel, or pellet. The ACP believes that injections are cheaper, yet just as effective as other methods and involve similar side effects. However, they recognize that injections (which will need to happen every 1-4 weeks) may not be for everyone.

Armin Brott is the author of Blueprint for Mens Health, Your Head: An Owners Manual, and many other works on mens health. Visit him at HealthyMenToday.com.

Continue reading here:
Healthy Men: Benefits of male hormone replacement therapy - Duluth News Tribune

The Testosterone Replacement Therapy Market Research Report aims to provide insights that strongly demonstrate the market structure, scope, history, potential, and development perspective. By crossing through the historical and present market status, the Testosterone Replacement Therapy market report provides authentic and reliable estimates for the forecast period.

It became essential to distinguish the saturation of consumption in the Testosterone Replacement Therapy market owing to building competitiveness. Hence, the report furnishes a deep-felt market segmentation analysis based on several segments such as types, applications, regions, and end-users. It serves to precise target the actual market size and product and service needs of customers. It also helps industry companies in promoting products that completely meet emerging customer needs.

Collect sample copy of the Testosterone Replacement Therapy market research at: https://www.amplemarketreports.com/sample-request/global-testosterone-replacement-therapy-market-1308418.html

The report furnishes the analysis of market encounter, segmentation, leading market players, industry environment, and microeconomic factors that help clients, Testosterone Replacement Therapy companies, investors, officials, and researchers perceive ongoing market performance within a minute. The report also reveals in-depth details of shifting market dynamics, pricing structures, trends, restraints, limitations, demand-supply variations, growth-boosting factors, and market variations that have been considered the most important factors in the Testosterone Replacement Therapy market.

Comprehensive analysis of Testosterone Replacement Therapy market segment by manufactures:

The report also highlights its financial position by assessing gross margin, profitability, production cost, pricing structure, expenses, Testosterone Replacement Therapy sales volume, revenue, and growth rate. Their raw material sourcing strategies, organizational structure, corporate alliance, Testosterone Replacement Therapy production volume, manufacturing base, sales areas, distribution network, global presence, product specifications, effective technologies, major vendors, and import-export activities are also emphasized in this report.

The report includes profound importance for the individuals/companies operating and financing in the Testosterone Replacement Therapy market as AbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, it holds helpful insights that immediate to discover and interpret market demand, market size, share, and rivalry sitch. The report incorporates comprehensive market intelligence procured using both qualitative and quantitative research methods. It also contracts proficient systematic analytical studies including Porters Five Forces, SWOT analysis, and Probability analysis to review the market thoroughly.

Find out more about competitive landscape at: https://www.amplemarketreports.com/report/global-testosterone-replacement-therapy-market-1308418.html

The report moreover presents a comprehensive representation of Testosterone Replacement Therapy manufacturers and companies who have been attempting to pose their dominance in the market in terms of sales, revenue, and growth. The report traverses their applications such as product research, development, innovation, and technology appropriation which supports them deliver more efficient product lineup in the industry. Profitable business plans, including acquiring, mergers, ventures, amalgamations, as well as product launches, and brand promotions are also elucidating in the report.

Comprehensive analysis of Testosterone Replacement Therapy market segment Type, Application:

Furthermore, it explores various requisite segments of the global Testosterone Replacement Therapy market such as types, applications, regions, and technologies. The report grants a comprehensive analysis of each market acknowledging market acceptance, attractiveness, demand, production, and predicted sales revenue by Type(Gels, Injections, Patches, Other) and by Application(Hospitals, Clinics, Others). The segmentation analysis helps consumers to select suitable segments for their Testosterone Replacement Therapy business and specifically target the wants and needs of their existing and potential customer base.

Comprehensive analysis of Testosterone Replacement Therapy market segment by Regional Anlaysis:

The report focuses on regional coverage across the globe principally with respect to x-x Units, revenue (Million USD), market share and growth rate variable with in each region depending upon its capacity. Regions that have been covered for this market included Asia-Pacific, Europe, North America, Middle East & Africa, South America

Discount, Know more this research report at: https://www.amplemarketreports.com/discount-request/global-testosterone-replacement-therapy-market-1308418.html

Thanks for reading this article, you can also get individual chapter wise section or region wise report versions like North America, Western / Eastern Europe or Southeast Asia.

With the given market data, Research on Global Markets offers customizations according to specific needs. Write to AMR at sales@amplemarketreports.com, or connect via +1-530-868-6979

About Author

Ample Market Research provides comprehensive market research services and solutions across various industry verticals and helps businesses perform exceptionally well. Our end goal is to provide quality market research and consulting services to customers and add maximum value to businesses worldwide. We desire to delivery reports that have the perfect concoction of useful data. Our mission is to capture every aspect of the market and offer businesses a document that makes solid grounds for crucial decision making.

Contact Address:

William James

Media & Marketing Manager

Address: 3680 Wilshire Blvd, Ste P04 1387 Los Angeles, CA 90010

Call: +1 (530) 868 6979

Email: sales@amplemarketreports.com

https://www.amplemarketreports.com

Read the original here:
Testosterone Replacement Therapy Market is Estimated to Grow at the Highest Growth Rate till 2020-2024 - Expedition 99